[1]
|
Apaydın, H., Bicer, C., Yurt, E., et al. (2022) AB0552 Elevated Kynurenine Levels in Patients with Primary Sjögren’s Syndrome. Annals of the Rheumatic Diseases, 81, 1401-1403. https://doi.org/10.1136/annrheumdis-2022-eular.4493
|
[2]
|
Foguem, C., Seror, R. and Gosset, M. (2022) Chemosensory Dysfunction in Primary Sjögren’s Syndrome: A Topical Review. Clinical Rheumatology, 42, 1-14. https://doi.org/10.1007/s10067-022-06359-w
|
[3]
|
Isaacson, P.G. and Wright, D. (1983) Malignant Lymphoma of Mucosa-Associated Lymphoid Tissue—A Distinctive Type of B-Cell Lymphoma. Cancer, 52, 1410-1416. https://doi.org/10.1002/1097-0142(19831015)52:8<1410::AID-CNCR2820520813>3.0.CO;2-3
|
[4]
|
Jo, V. and Fletcher, C. (2013) WHO Classification of Soft Tissue Tumours. Pathology, 46, 95-104.
|
[5]
|
Vallabhapurapu, S. and Karin, M. (2009) Regulation and Function of NF-κB Transcription Factors in the Immune System. Annual Review of Immunology, 27, 693-733. https://doi.org/10.1146/annurev.immunol.021908.132641
|
[6]
|
Zhu, H., Zheng, J., Zhou, Y., et al. (2021) Knockdown of RSAD2 Attenuates B Cell Hyperactivity in Patients with Primary Sjögren’s Syndrome (PSS) via Suppressing NF-κB Signaling Pathway. Molecular and Cellular Biochemistry, 476, 2029-2037. https://doi.org/10.1007/s11010-021-04070-z
|
[7]
|
Beinke, S. and Ley, S.C. (2004) Functions of NF-KappaB1 and NF-KappaB2 in Immune Cell Biology. Biochemical Journal, 382, 393-409. https://doi.org/10.1042/BJ20040544
|
[8]
|
Nordmark, G., Wang, C., Vasaitis, L., et al. (2013) Association of Genes in the NF‐κB Pathway with Antibody‐Positive Primary Sjögren’s Syndrome. Scandinavian Journal of Immunology, 78, 447-454. https://doi.org/10.1111/sji.12101
|
[9]
|
Nocturne, G., Boudaoud, S., Miceli, C., et al. (2013) Germline and Somatic Genetic Variations of TNFAIP3 in Lymphoma Complicating Primary Sjogren’s Syndrome. Blood, 122, 4068-4076. https://doi.org/10.1182/blood-2013-05-503383
|
[10]
|
Nocturne, G., Tarn, J., Boudaoud, S., et al. (2015) Germline Variation of TNFAIP3 in Primary Sjögren’s Syndrome-Associated Lymphoma: Table 1. Annals of the Rheumatic Diseases, 75, 780-783. https://doi.org/10.1136/annrheumdis-2015-207731
|
[11]
|
Nocturne, G., Virone, A., Ng, W.-F., et al. (2015) Rheumatoid Factor and Disease Activity Are Independent Predictors of Lymphoma in Primary Sjögren’s Syndrome. Arthritis & Rheumatology (Hoboken, N.J.), 68, 977-985. https://doi.org/10.1002/art.39518
|
[12]
|
Chen, W., Lin, J., Cao, H., et al. (2015) Local and Systemic IKKε and NF-κB Signaling Associated with Sjögren’s Syndrome Immunopathogenesis. Journal of Immunology Research, 2015, Article ID: 534648. https://doi.org/10.1155/2015/534648
|
[13]
|
Tilioua, S., Mezioug, D., Amir-Tidadini, Z.C., et al. (2020) Potential Role of NF-κB Pathway in the Immuno-Inflammatory Responses during Human Cystic Echinococcosis. Acta Tropica, 203, Article ID: 105306. https://doi.org/10.1016/j.actatropica.2019.105306
|
[14]
|
Wei, H., Wang, B., Miyagi, M., et al. (2013) PRMT5 Dimethylates R30 of the P65 Subunit to Activate NF-κB. Proceedings of the National Academy of Sciences of the United States of America, 110, 13516-13521. https://doi.org/10.1073/pnas.1311784110
|
[15]
|
Hoshida, Y., Xu, J.X., Fujita, S., et al. (2007) Lymphoproliferative Disorders in Rheumatoid Arthritis: Clinicopathological Analysis of 76 Cases in Relation to Methotrexate Medication. The Journal of Rheumatology, 34, 322-331.
|
[16]
|
Okabe, M., Inagaki, H., Ohshima, K., et al. (2003) API2-MALT1 Fusion Defines a Distinctive Clinicopathologic Subtype in Pulmonary Extranodal Marginal Zone B-Cell Lymphoma of Mucosa-Associated Lymphoid Tissue. The American Journal of Pathology, 162, 1113-1122. https://doi.org/10.1016/S0002-9440(10)63908-9
|
[17]
|
Remstein, E.D., Kurtin, P.J., Einerson, R.R., et al. (2004) Primary Pulmonary MALT Lymphomas Show Frequent and Heterogeneous Cytogenetic Abnormalities, Including Aneuploidy and Translocations Involving API2 and MALT1 and IGH and MALT1. Leukemia, 18, 156-160. https://doi.org/10.1038/sj.leu.2403185
|
[18]
|
Streubel, B., Simonitsch-Klupp, I., Müllauer, L., et al. (2004) Variable Frequencies of MALT Lymphoma-Associated Genetic Aberrations in MALT Lymphomas of Different Sites. Leukemia, 18, 1722-1726. https://doi.org/10.1038/sj.leu.2403501
|
[19]
|
Reichenberger, F., Wyser, C., Gonon, M., et al. (2001) Pulmonary Mucosa-Associated Lymphoid Tissue Lymphoma in a Patient with Common Variable Immunodeficiency Syndrome. Respiration, 68, 109-112. https://doi.org/10.1159/000050475
|
[20]
|
Borie, R., Wislez, M., Thabut, G., et al. (2009) Clinical Characteristics and Prognostic Factors of Pulmonary MALT Lymphoma. European Respiratory Journal, 34, 1408-1416. https://doi.org/10.1183/09031936.00039309
|
[21]
|
Alu, A., Lei, H., Han, X., et al. (2022) BTK Inhibitors in the Treatment of Hematological Malignancies and Inflammatory Diseases: Mechanisms and Clinical Studies. Journal of Hematology & Oncology, 15, Article No. 138. https://doi.org/10.1186/s13045-022-01353-w
|
[22]
|
Burger, J.A. (2019) Bruton Tyrosine Kinase Inhibitors: Present and Future. The Cancer Journal, 25, 386-393. https://doi.org/10.1097/PPO.0000000000000412
|
[23]
|
Fares, A., Uribe, C., Rehman, T., et al. (2024) Bruton’s Tyrosine Kinase Inhibitors: Recent Updates. International Journal of Molecular Sciences, 25, Article No. 2208. https://doi.org/10.3390/ijms25042208
|
[24]
|
Mano, H. (1999) Tec Family of Protein-Tyrosine Kinases: An Overview of Their Structure and Function. Cytokine & Growth Factor Reviews, 10, 267-280. https://doi.org/10.1016/S1359-6101(99)00019-2
|